EZH2 and neoplasm: Selective inhibition of Enhancer of Zeste Homolog 2 (EZH2), using CPI-1205, in a murine MC-38 cancer model disrupted the immunosuppressive function of tumor infiltrating Tregs, skewing their response towards a more pro-inflammatory phenotype.